SwePub
Sök i LIBRIS databas

  Extended search

(swepub) lar1:(umu)
 

Search: (swepub) lar1:(umu) > (2000-2009) > Successful mobiliza...

  • Olsson-Strömberg, UllaUppsala universitet,Institutionen för medicinska vetenskaper,Hematologi (author)

Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase

  • Article/chapterEnglish2006

Publisher, publication year, extent ...

  • 2009-07
  • Informa UK Limited,2006
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:oru-12052
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-12052URI
  • https://doi.org/10.1080/10428190600611117DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-16148URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-95820URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:1940578URI
  • https://lup.lub.lu.se/record/378698URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-37789URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-22582URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • The aim of the study was to investigate the feasibility of mobilizing Philadelphia chromosome negative (Ph-) blood stem cells (BSC) with intensive chemotherapy and lenograstim (G-CSF) in patients with CML in first chronic phase (CP1). During 1994-1999 12 centers included 37 patients <56 years. All patients received 6 months' IFN, stopping at median 36 (1-290) days prior to the mobilization chemotherapy. All received one cycle of daunorubicin 50 mg/m2 and 1 hour infusion on days 1-3, and cytarabine (ara-C) 200 mg/m2 24 hours' i.v. infusion on days 1-7 (DA) followed by G-CSF 526 microg s.c. once daily from day 8 after the start of chemotherapy. Leukaphereses were initiated when the number of CD 34+ cells was >5/microl blood. Patients mobilizing poorly could receive a 4-day cycle of chemotherapy with mitoxantrone 12 mg/m2/day and 1 hour i.v infusion, etoposide 100 mg/m2/day and 1 hour i.v. infusion and ara-C 1 g/m2/twice a day with 2 hours' i.v infusion (MEA) or a second DA, followed by G-CSF 526 microg s.c once daily from day 8 after the start of chemotherapy. Twenty-seven patients received one cycle of chemotherapy and G-CSF, whereas 10 were mobilized twice. Twenty-three patients (62%) were successfully (MNC >3.5 x 10(8)/kg, CFU-GM >1.0 x 10(4)/kg, CD34+ cells >2.0 x 10(6)/kg and no Ph+ cells in the apheresis product) [n = 16] or partially successfully (as defined above but 1-34% Ph+ cells in the apheresis product) [n = 7] mobilized. There was no mortality during the mobilization procedure. Twenty-one/23 patients subsequently underwent auto-SCT. The time with PMN <0.5 x 10(9)/l was 10 (range 7-49) and with platelets <20 x 10(9)/l was also 10 (2-173) days. There was no transplant related mortality. The estimated 5-year overall survival after auto-SCT was 68% (95% CI 47 - 90%), with a median follow-up time of 5.2 years.We conclude that in a significant proportion of patients with CML in CP 1, intensive chemotherapy combined with G-CSF mobilizes Ph- BSC sufficient for use in auto-SCT.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Höglund, MartinUppsala universitet,Institutionen för medicinska vetenskaper,Hematologi (author)
  • Björkholm, MagnusKarolinska Institutet (author)
  • Braide, Inger (author)
  • Carlson, Karin (author)
  • Gahrton, GöstaKarolinska Institutet (author)
  • Grimfors, Gunnar (author)
  • Hast, RobertKarolinska Institutet (author)
  • Lerner, Rickard (author)
  • Linder, Olle (author)
  • Ljungman, PerKarolinska Institutet (author)
  • Löfvenberg, Eva (author)
  • Malm, Claes,1945-Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Onkologi,Hematologiska kliniken US(Swepub:liu)clama59 (author)
  • Nilsson, Per-GunnarLund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine(Swepub:lu)med-pni (author)
  • Paul, ChristerKarolinska Institutet (author)
  • Rödjer, Stig (author)
  • Stenke, LeifKarolinska Institutet (author)
  • Tidefelt, UlfÖrebro universitet,Institutionen för klinisk medicin(Swepub:oru)uftt (author)
  • Turesson, Ingemar (author)
  • Udén, Ann-Marie (author)
  • Wahlin, AndersUmeå universitet,Institutionen för folkhälsa och klinisk medicin(Swepub:umu)anwa0027 (author)
  • Vilén, Lars (author)
  • Winqvist, Ingemar (author)
  • Zettervall, Olle (author)
  • Öberg, GunnarUppsala universitet,Institutionen för medicinska vetenskaper,Hematologi (author)
  • Simonsson, BengtUppsala universitet,Institutionen för medicinska vetenskaper,Hematologi (author)
  • Winqvist, Gunnar (author)
  • Uppsala universitetInstitutionen för medicinska vetenskaper (creator_code:org_t)

Related titles

  • In:Leukemia and Lymphoma: Informa UK Limited47:9, s. 1768-731042-81941029-2403
  • In:Leuk Lymphoma: Informa UK Limited47:9, s. 1768-73

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view